EA201001407A1 - Производные хиноксалинона в качестве стимуляторов секреции инсулина, способы их получения и их применение для лечения диабета - Google Patents

Производные хиноксалинона в качестве стимуляторов секреции инсулина, способы их получения и их применение для лечения диабета

Info

Publication number
EA201001407A1
EA201001407A1 EA201001407A EA201001407A EA201001407A1 EA 201001407 A1 EA201001407 A1 EA 201001407A1 EA 201001407 A EA201001407 A EA 201001407A EA 201001407 A EA201001407 A EA 201001407A EA 201001407 A1 EA201001407 A1 EA 201001407A1
Authority
EA
Eurasian Patent Office
Prior art keywords
diabetes
treatment
derivatives
insulin
chinoxalinon
Prior art date
Application number
EA201001407A
Other languages
English (en)
Other versions
EA021904B1 (ru
Inventor
Жерар Боттон
Эрик Валёр
Мишлине Кергоат
Кристине Шарон
Самер Эльбаваб
Original Assignee
Мерк Патент Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Мерк Патент Гмбх filed Critical Мерк Патент Гмбх
Publication of EA201001407A1 publication Critical patent/EA201001407A1/ru
Publication of EA021904B1 publication Critical patent/EA021904B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40—Benzopyrazines
    • C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Настоящее изобретение относится к производным хиноксалинона формулы (I)где R1, R2, R3, R4, R5 и R6 принимают значения, определенные в п.1, в качестве стимуляторов секреции инсулина. Изобретение также относится к получению и применению этих производных хиноксалинона для профилактики и/или лечения диабета и связанных с ним патологий. Другими предпочтительными соединениями являются соединения общей формулы (I), где R1, R2, R3, R4, R5 и R6 необязательно могут быть замещены одной или несколькими группами, выбранными из Z.
EA201001407A 2008-03-05 2009-01-15 Производные хиноксалинона в качестве стимуляторов секреции инсулина, способы их получения и их применение для лечения диабета EA021904B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08004053 2008-03-05
PCT/EP2009/000209 WO2009109258A1 (en) 2008-03-05 2009-01-15 Quinoxalinone derivatives as insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes

Publications (2)

Publication Number Publication Date
EA201001407A1 true EA201001407A1 (ru) 2011-06-30
EA021904B1 EA021904B1 (ru) 2015-09-30

Family

ID=40547943

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201001407A EA021904B1 (ru) 2008-03-05 2009-01-15 Производные хиноксалинона в качестве стимуляторов секреции инсулина, способы их получения и их применение для лечения диабета

Country Status (18)

Country Link
US (2) US8415352B2 (ru)
EP (1) EP2247580B1 (ru)
JP (1) JP5618837B2 (ru)
KR (1) KR101637387B1 (ru)
CN (1) CN101952258B (ru)
AR (1) AR070797A1 (ru)
AU (1) AU2009221327B2 (ru)
BR (1) BRPI0908406B8 (ru)
CA (1) CA2717718C (ru)
DK (1) DK2247580T3 (ru)
EA (1) EA021904B1 (ru)
ES (1) ES2548583T3 (ru)
HU (1) HUE027811T2 (ru)
IL (1) IL207720A (ru)
MX (1) MX2010009576A (ru)
PT (1) PT2247580E (ru)
WO (1) WO2009109258A1 (ru)
ZA (1) ZA201007059B (ru)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
HUE054031T2 (hu) 2012-04-24 2021-08-30 Vertex Pharma DNS-PK inhibitorok
HUE041544T2 (hu) 2013-03-12 2019-05-28 Vertex Pharma DNS-PK inhibitorok
SI3057953T1 (sl) 2013-10-17 2018-12-31 Vertex Pharmaceuticals Incorporated Ko-kristali(s)-n-metil-8-(1-((2'-metil-(4,5'-bipimiridin)-6-il)amino) propan-2-il)kinolin-4-karboksamida in njegovi devterirani derivati kot inhibitorji dna-pk
CN104628661A (zh) * 2015-02-05 2015-05-20 北京理工大学 一类喹喔啉酮衍生物作为醛糖还原酶抑制剂的结构、制备方法及用途
ES2901002T3 (es) 2015-12-24 2022-03-21 Univ California Derivados de N-[5-[(3,4-dimetoxifenil)metil]-1,3,4-tiadiazol-2-il]-2-metoxi-bencenoacetamida y compuestos relacionados como activadores de CFTR para tratar estreñimiento o colestasis
KR20180101416A (ko) * 2015-12-24 2018-09-12 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 Cftr 조절제 및 이의 이용 방법
AU2016379444B2 (en) 2015-12-24 2021-04-29 The Regents Of The University Of California CFTR regulators and methods of use thereof
CN105769870A (zh) * 2016-04-09 2016-07-20 李曼 一种治疗糖尿病的药物
CA3038657A1 (en) 2016-09-27 2018-04-05 Vertex Pharmaceuticals Incorporated Method for treating cancer using a combination of dna-damaging agents and dna-pk inhibitors
KR20200044873A (ko) 2017-08-24 2020-04-29 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 안구 제약학적 조성물
CN109793739A (zh) * 2019-01-14 2019-05-24 北京理工大学 一种喹喔啉酮衍生物的结构、制备方法及用途
CN109796417A (zh) * 2019-01-14 2019-05-24 北京理工大学 一系列喹喔啉酮衍生物的结构、制备方法及用途
CN114957222B (zh) * 2022-05-31 2023-08-15 内蒙古民族大学 化合物及其制备方法和用途
CN114907323B (zh) * 2022-05-31 2023-08-15 内蒙古民族大学 喹喔啉酮类化合物及其制备方法和应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU410015A1 (ru) * 1971-06-22 1974-01-05
SU616955A1 (ru) * 1977-03-02 2006-12-27 Пермский ордена Трудового Красного Знамени государственный университет им.А.М.Горького 2-(α-бромфенацил)-хиноксалон-3, проявляющий противовоспалительную активность
US4181724A (en) * 1978-09-11 1980-01-01 The Upjohn Company Quinoxalinone compounds useful for expanding the lumina or air passages in mammals
FR2653430B1 (fr) * 1989-10-23 1991-12-20 Pf Medicament Nouveaux derives de dihydro-1,2 oxo-2 quinoxalines, leur preparation et leur application en therapeutique.
BR9810456A (pt) 1997-06-27 2001-09-25 Fujisawa Pharmaceutical Co Composto de sulfonamida, método para sua obtenção e seu uso farmacêutico
KR100588247B1 (ko) * 1997-09-01 2006-06-13 교린 세이야꾸 가부시키 가이샤 6,7-비대칭 이치환된 퀴녹살린카복실산 유도체와 이의부가염 및 이들의 제조방법
HUP0101470A3 (en) 1998-03-31 2002-09-30 Warner Lambert Co Quinoxalinones as serine protease inhibitors such as factor xa and thrombin and medicaments containing the compounds
DE10343098A1 (de) * 2003-09-18 2005-04-14 Bayer Healthcare Ag Tetrahydrochinoxaline und ihre Verwendung
EA200601287A1 (ru) * 2004-01-06 2006-10-27 Янссен Фармацевтика, Н.В. Производные (3-оксо-3,4-дигидрохиноксалин-2-иламино) бензамида и родственные соединения в качестве ингибиторов гликогенфосфорилазы для лечения диабета и ожирения
DE102004023332A1 (de) * 2004-05-12 2006-01-19 Bayer Cropscience Gmbh Chinoxalin-2-on-derivate, diese enthaltende nutzpflanzenschützende Mittel und Verfahren zu ihrer Herstellung und deren Verwendung
WO2007135527A2 (en) * 2006-05-23 2007-11-29 Pfizer Products Inc. Benzimidazolyl compounds

Also Published As

Publication number Publication date
KR101637387B1 (ko) 2016-07-07
BRPI0908406A2 (pt) 2015-08-11
IL207720A0 (en) 2010-12-30
AR070797A1 (es) 2010-05-05
US8415352B2 (en) 2013-04-09
ES2548583T3 (es) 2015-10-19
AU2009221327B2 (en) 2014-03-27
CA2717718C (en) 2016-05-31
KR20100123899A (ko) 2010-11-25
EP2247580A1 (en) 2010-11-10
MX2010009576A (es) 2010-09-24
US20110015194A1 (en) 2011-01-20
DK2247580T3 (en) 2015-10-05
US20130123257A1 (en) 2013-05-16
AU2009221327A1 (en) 2009-09-11
HUE027811T2 (en) 2016-11-28
CN101952258A (zh) 2011-01-19
BRPI0908406B8 (pt) 2023-02-07
IL207720A (en) 2014-12-31
CA2717718A1 (en) 2009-09-11
JP5618837B2 (ja) 2014-11-05
PT2247580E (pt) 2015-10-19
WO2009109258A1 (en) 2009-09-11
US8835634B2 (en) 2014-09-16
EP2247580B1 (en) 2015-07-08
ZA201007059B (en) 2011-06-29
BRPI0908406B1 (pt) 2019-04-09
CN101952258B (zh) 2014-03-19
JP2011513343A (ja) 2011-04-28
EA021904B1 (ru) 2015-09-30

Similar Documents

Publication Publication Date Title
EA201001407A1 (ru) Производные хиноксалинона в качестве стимуляторов секреции инсулина, способы их получения и их применение для лечения диабета
EA201070422A1 (ru) Производные оксадиазола
TW200745004A (en) Novel compounds, their preparation and use
EA201200119A1 (ru) Гетероциклические соединения в качестве ингибиторов аутотаксина
EA201101399A1 (ru) Гетероциклические соединения в качестве ингибиторов аутотаксина
EA201200653A1 (ru) Гетариламинохинолины
TN2011000279A1 (en) Novel pyrazole -4-n-alkoxycarboxamides as microbiocides
NO20083514L (no) Heterobicykliske sulfonamidderivater for behandling av diabetes
EA201171211A1 (ru) Производные оксадиазола
PH12013500848A1 (en) Trpv1 antagonists and uses thereof
UA97817C2 (ru) Гетероциклические производные 4-(метилсульфонил)фенила и их применение
EA201001408A1 (ru) Производные пиразинона как стимуляторы секреции инсулина, способы их получения и их применение для лечения диабетов
PE20081806A1 (es) Imidazo- y triazolopirimidinas sustituidas
GEP20146102B (en) Compounds and compositions as protein kinase inhibitors
MY149648A (en) Carboxylalkylene-phenyl)-phenyl-oxalamides, method for the production thereof, and use of same as a medicament
EA201000550A1 (ru) Производные тиазола
MA32505B1 (fr) 5-alcynyl-pyrimidines
MX2010005033A (es) Aminas heterociclicas fungicidas.
JO2682B1 (en) Derivatives of alkynil-8.1-naphthayridone, preparations thereof and therapeutic use thereof
MX2012007582A (es) Compuestos de 4-fenoxi-nicotinamida o 4-fenoxi-pirimidina-5-carbox amida.
EA201201623A1 (ru) Лечение диабета 2 типа
EA201070779A1 (ru) Триазолсодержащие производные оксадиазола
MX2011008360A (es) Derivados de piridazinona sustituida con heteroarilo.
IL207639A (en) PyrrollopyrimidineCarboxylate compounds, preparations containing them and their uses
EA201070281A1 (ru) Производные индол-2-она, двузамещенные в положении 3, их получение и их применение в терапии

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM